• March 19, 2002

    Mirror Stars

    No longer can I say that the topic of allergenic extraterrestrial life hasn’t been taken on in science fiction. Patrick Neilsen Hayden of Electrolite, who is certainly in a professional position to know, passes on the word that the 1999 novel BIOS (by Robert Charles Wilson, reviewed) includes this very idea. On a related topic… Read More
  • March 10, 2002

    Separation Anxiety

    Sepracor‘s really taken a pounding after an FDA “non-approvable” letter for their antihistamine compound. But they haven’t been a quiet drug stock to be in, and it isn’t a quiet company. They certainly don’t have a quiet business plan, either. As readers who are in the business are well aware, Sepracor doesn̵… Read More
  • February 27, 2002

    More Imclone, More Food for Thought

    As you’ve no doubt heard, Imclone issued a press release this morning about their FDA meeting. It seems that if they can come up with more clinical data from Merck KGaA’s European trials, along with clarifying some of their own numbers, then the FDA has agreed to look at a resubmission. Bristol Meyers-Squibb has been… Read More
  • Who Dares, Wins?

    I’d like to take the time to sympathize with Elan Pharmaceuticals over what’s happened to their Alzheimer’s trial. They had the initiative (and the nerve) to pick up and run with an unusual discovery: that a protein that precipitates in the brains of Alzheimer’s patients, beta-amyloid, can be attacked by an immune response.… Read More
  • February 26, 2002

    A Certain Tension in the Air

    Well, today is Imclone day at the FDA (see Jan 31 and Feb. 6 postings.) All parties will be meeting to decide what the path forward is: reworking the existing data, supplementing it with whatever else the companies can dredge up, or new clinical trials. Analysts have raised the possibility of using some clinical data… Read More
  • New Drugs for HIV

    Megan McArdle points out the recent news (which has shown up in Tuesday’s NY Times and other outlets as well) about new HIV treatments with possibly fewer side effects. She asks if the same technique can be applied to other diseases, and I thought for the benefit of the non-pharma audience that I’d go into… Read More
  • February 25, 2002

  • February 24, 2002


    I’ll continue to talk now and then about some topics that won’t necessarily be news to those inside the pharma industry. I see from my traffic stats that most of the hits are from outside it, although there are increasing numbers from both my own company and the competition. Thoughts of work prompt me to… Read More
  • February 22, 2002

    Cartesian Aging

    As I mentioned previously, I’ve been reading the letters of both Kingsley Amis and Philip Larkin. One thing you notice in any Collected Letters book (try Evelyn Waugh’s) is old age creeping up on the writers. It’s less noticable in Larkin’s case; his personality famously made him sound about 70 years old for decades. But… Read More
  • February 20, 2002

    Giordano Bruno

    I missed a chance yesterday to note an anniversary. Giordano Bruno was something of a crank, not normally the sort of person I’d be commemorating. But in his time, it didn’t take very much to be considered either of those, or worse, and we have to make allowances. He was headstrong. We can see now… Read More
Page 524 of 525« First...102030...521522523524525